can we improve on r-chop for the frontline treatment of dlbcl?
Published 5 years ago • 272 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
2:15
frontmind: tafasitamab lenalidomide r-chop vs r-chop for newly diagnosed high-risk dlbcl
-
5:30
how the treatment landscape of dlbcl is changing: r-chop vs pola-r-chp
-
1:57
r-chop dose intensity and survival outcomes in dlbcl
-
1:12
smart stop: moving away from r-chop in dlbcl
-
1:44
remodl-b: bortezomib r-chop versus r-chop in patients with dlbcl
-
0:42
targeted therapies for dlbcl treatment
-
6:12
coalition: glofitamab r-chop or glofitamab pola-r-chp in patients with high-risk dlbcl
-
6:42
diffuse large b-cell lymphoma - diagnosis& treatment - aggressive b-cell non-hodgkin’s lymphoma
-
6:35
high grade diffuse large b-cell lymphoma: carole's story
-
10:07
understanding diffuse large b-cell lymphoma with bruce cheson, md, facp, faaas, fasco
-
1:00
phase ib trial of r-chop plus iberdomide or cc-99282 in aggressive b-cell lymphoma
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
1:45
ham-ven as salvage treatment for r/r aml: results from the sal-relax trial
-
16:10
is frontline r-chop still the standard of care for dlbcl?
-
2:33
tailoring chemotherapy: r-chop dose attenuation in elderly dlbcl
-
2:00
the use of chemotherapy in r/r hodgkin and non-hodgkin lymphomas
-
1:23
findings from the ro-chop trial in patients with r/r ptcl
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
0:45
difference between quality of life & patient-reported outcomes
-
1:52
implementing ai in hematology and the challenges this will overcome
-
1:55
the real-world efficacy of brentuximab vedotin consolidation post-autosct in r/r hl
-
3:32
improving car-t therapy for all & lymphoma: allogeneic products & reducing crs/icans